A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
Study Details
Study Description
Brief Summary
The study is to demonstrate non-inferior thyroid remnant first ablation success of Thyrogen and 131I compared to thyroid hormone withdrawal (THW) and 131I in patients with T4 tumour based on historical diagnostic whole body scan (DxWBS) records.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Thyrogen and 131I Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I. |
Drug: Thyrogen
0.9 mg IM, administrated for 2 consecutive days
Drug: 131I
28 mCi or ≥ 1.036 GBq.
|
| Thyroid Hormone Withdrawal and 131I Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I. |
Drug: 131I
28 mCi or ≥ 1.036 GBq.
Other: Thyroid Hormone Withdrawal
Stop taking hormone therapy
|
Outcome Measures
Primary Outcome Measures
- First ablation success rate by Diagnostic Whole Body Scan (DxWBS) [at least 6 months after administration of first ablation activity of 131I]
Secondary Outcome Measures
- First ablation success rate based on stimulated Thyroglobulin (Tg) levels [at least 6 months after administration of first ablation activity of 131I]
- First ablation success rate based on historical records [at least 6 months after administration of first ablation activity of 131I]
- Number of adverse events of Thyrogen and 131I arm and THW and 131I arm [Within 30 days of treatment.]
Exploratory safety assessment in patients with T4 tumour for first ablation of thyroid remnants based on historical records.
Eligibility Criteria
Criteria
Inclusion Criteria:
Historical records from patients who meet all of the following criteria will be eligible for inclusion in this retrospective evaluation:
-
Male or female patients living or deceased, aged 18 years or older at the time of first ablation for thyroid cancer.
-
Diagnosed with a well-differentiated T4 tumour (defined as a primary tumour of any size that extends beyond the thyroid capsule [this may be referred to as TNM classification T4, N0-1, M0-1]). This excludes unusual histological types such as oncocytic (Hurthle cell carcinoma), tall cell, sclerosing or cribriform thyroid cancers.
-
Undergone a near-total or total thyroidectomy on or after 01 January 2000
-
Undergone first ablation of thyroid remnants with high activity 131I (≥28 mCi or ≥ 1.036 GBq).
-
Undergone first 131I ablation for the T4 tumour using either Thyrogen (0.9 mg IM on 2 consecutive days) or THW stimulation. This excludes use of non-standard Thyrogen regimens (i.e., had a regimen of Thyrogen other than the standard 0.9 mg IM on 2 consecutive days or received Thyrogen in combination with THW).
-
Historical records are available confirming ablation results by:
-
DxWBS using small activity (≥2 mCi or 74 MBq) of iodine 131I (or 123I) performed at least 6 months after administration of the first ablation activity of 131I and/or
-
Stimulated Tg measured at least 6 months after administration of the first ablation activity of 131I.
Exclusion Criteria:
Historical records from patients who meet any of the following criteria will be excluded from this retrospective evaluation:
-
Received propylthiouracil, methimazole, vitamins or supplements containing kelp or iodine (taking a multivitamin that does not contain iodine or kelp is acceptable), medications that significantly affect iodine handling such as high dose corticosteroids, high dose diuretics, or lithium in the 45 days before administration of first ablative activity of 131I.
-
Received any iodine-containing contrast agents within 3 months prior to first ablative activity of 131I administered.
-
Used amiodarone within the 2 years prior to first ablative activity of 131I administered.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hanover University School of Medicine | Hannover | Germany | ||
| 2 | Klinikum Großhadern | München | Germany | ||
| 3 | Policlinico S.Orsola-Malpighi | Bologna | Italy | ||
| 4 | Instituto Oncologico Veneto | Padova | Italy | ||
| 5 | Istituti Fisioterapici Ospitalieri (IFO) | Rome | Italy | ||
| 6 | Portuguese Institute of Oncology | Coimbra | Portugal | ||
| 7 | Hospital Universitario Reina Sofía | Cordoba | Spain | ||
| 8 | Hospital Universitario Virgen de las Nieves | Granada | Spain | ||
| 9 | Hospital Universitario Dr Peset | Valencia | Spain |
Sponsors and Collaborators
- Genzyme, a Sanofi Company
Investigators
- Study Director: Medical Monitor, Genzyme, a Sanofi Company
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- THYR04910